Showing 5031-5040 of 8550 results for "".
- Oculus Innovative Sciences' Microcyn®-based Lasercyn™ Gel Cleared for Post-procedure Usehttps://practicaldermatology.com/news/oculus-innovative-sciences-microcyn-based-lasercyn-gel-cleared-for-post-procedure-use/2458597/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for the company's new Microcyn®-based Lasercyn™ Gel. Under the supervision of a healthcare professional, Lasercyn Gel is int
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC
- Checkpoint Inhibitor Shows Promise in MCChttps://practicaldermatology.com/news/checkpoint-inhibitor-shows-promise-in-mcc/2458603/Advanced Merkel cell carcinoma patients who received KEYTRUDA® (pembrolizumab) showed more durable responses than what is typically seen with standard chemotherapy, according to a study presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans and simul
- New MRF White Paper Provides Road Map for Eradicating Melanomahttps://practicaldermatology.com/news/new-mrf-white-paper-provides-road-map-for-eradicating-melanoma/2458604/More research needs to be done about what range of wavelengths in the ultraviolet band need to be blocked to prevent melanoma, according to a new white paper from Melanoma Research Foundation (MRF). The paper, "The Stat
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- AAD Announces New Officers and Board Membershttps://practicaldermatology.com/news/aad-announces-new-officers-and-board-members/2458608/The American Academy of Dermatology (AAD) announced the results of its annual election. These new officers and board members also will hold the same positions for the American Academy of Dermatology Association. Suzanne Olbricht, MD, FAAD will take the office of Academy president-elect. D
- Avalere: Biosimilars More Expensive for Medicare Beneficiarieshttps://practicaldermatology.com/news/avalere-biosimilars-more-expensive-for-medicare-beneficiaries/2458610/Medicare beneficiaries are likely to pay more for biosimilars than for the biologic reference product in Part D under current law, according to a new report from
- Kourtney Kardashian is Manuka Doctor's New Brand Ambassadorhttps://practicaldermatology.com/news/kourtney-kardashian-is-manuka-doctors-new-brand-ambassador/2458614/Kybella has Khloe, and now Manuka Doctors got Kourtney. Kourtney Kardashian is the new face of Manuka Doctor, a skincare line comprising Manuka Honey and patented Purified Bee Venom.
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria